Food and Drug Administration (FDA) Research Food and Drug Administration (FDA) RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Profiling lecanemab as a treatment option for Alzheimer's disease
Expert Rev Neurother. 2024 May;24(5):433-441. doi: 10.1080/14737175.2024.2333970. Epub 2024 Apr 3.ABSTRACTINTRODUCTION: In July 2023, the U.S. Food and Drug Administration (FDA) granted full approval to lecanemab for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD dementia. Considering the limited treatment options for AD, the approval of lecanemab offers hope and opens the door for other disease-modifying therapies in the pipeline.AREAS COVERED: In this review, the authors summarize the FDA treatment guidelines, other anti-amyloid agents, and drug information relevant to prescr...
Source: Expert Review of Neurotherapeutics - April 3, 2024 Category: Neurology Authors: Emily R Schiller Bret David Silverglate George T Grossberg Source Type: research

CB ‐0821, a novel CC chemokine receptor 5 (CCR5) inhibitor with improved binding efficacy proposed as anti‐HIV candidate: Computational and in vitro approach
In this study, CB-0821, identified from the ChemBridge library, emerged as a promising CCR5 inhibitor. Molecular dynamics simulations indicate comparable dynamic properties for CB-0821 and MVC. In silico comparisons with other CCR5 inhibitors emphasize CB-0821's superior binding affinity, positioning it as a potential lead compound. Evaluations of the dissociation constant (Ki) and absorption, distribution, metabolism, and excretion predictions suggest CB-0821 as a well-tolerated drug. Furthermore, the dose-dependent inhibition of CCR5 by CB-0821 in Peripheral blood mononuclear cells (PBMCs) (ranging from 10 to 200  nM) d...
Source: Biotechnology and Applied Biochemistry - April 3, 2024 Category: Biochemistry Authors: Ashish Kumar Tags: ORIGINAL ARTICLE Source Type: research

State of pneumococcal vaccine immunity
Volume 20, Issue 1, December 2024 . (Source: Human Vaccines and Immunotherapeutics)
Source: Human Vaccines and Immunotherapeutics - April 3, 2024 Category: Allergy & Immunology Authors: Mustafa AkkoyunluDivision of Bacterial Allergenic and Parasitic Diseases, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA Source Type: research

Aortic Regurgitation, Time to Aortic Valve Reintervention, and Mortality in Degenerated Trifecta Versus Non-Trifecta Bioprosthesis
The first Trifecta valve (Abbott, St Paul, Minnesota) was introduced in 2007, CE marked in 2010, and received US Food and Drug Administration (FDA) approval in 2011. An “improved” first-generation valve was introduced in 2015, with a second-generation Trifecta Glide Technology (GT) valve introduced in 2016 that received FDA approval the same year and with a new holder introduced with the later model in 2020. These stented valves touted a single bovine pericardi al tissue, externally mounted on a titanium stent that was designed for supra-annular placement. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - April 3, 2024 Category: Cardiology Authors: Amr E. Abbas, Luai Madanat, Houman Khalili, Ramy Mando, Mazhed Kheyrbek, Rohit Chandra, Shailesh Niroula, Ivan Hanson, Simon Dixon, Brian Renard, Richard Bloomingdale, Elvis Cami, Brittany Pridham, Jeffrey Altshuler, Bogdan Kindzelski, Franco Fazzalari, F Source Type: research